According to the most recent filing that Assenagon Asset Management S.A. has made with the Securities and Exchange Commission, the company made a new investment in AVITA Medical, Inc. (NASDAQ: RCEL) during the third quarter. The purchase of 33,493 shares of company stock cost the fund a total of close to $177,000 to complete the transaction. Assenagon Asset Management S.A. owned approximately 0.13 percent of AVITA Medical when the most recent reporting period closed.
There have been transactions with other hedge funds buying and selling business stock. These transactions took place. Amalgamated Bank kicked off a new investment strategy during the first three months of 2018, spending approximately $34,000 to buy shares of AVITA Medical. This was the bank’s first step in diversifying its portfolio. Rhumbline Advisers increased the percentage of ownership it holds in AVITA Medical by 23.3% over the first three months of 2018. As a result of the purchase of 4,326 additional shares during the most recent quarter, Rhumbline Advisers is now the owner of 22,913 shares of the company’s stock. The current value of these shares is $194,000; Rhumbline Advisers acquired these shares (22,913 shares). Over the first three months of the year, Vanguard Group Inc. increased the percentage of AVITA Medical stock owned by 0.5%. As a result of the purchase of an additional 6,467 shares during the most recent quarter, Vanguard Group Inc. now has a total of 1,276,977 shares in the company, which have a value of $10,830,000. The company acquired these shares. In the second quarter of 2018, AQR Capital Management LLC invested in AVITA Medical $48,000. During the first three months of the year, Engineers Gate Manager LP expanded its investment holdings by purchasing AVITA Medical shares worth one hundred thousand dollars. At present, institutions own 17.22% of the total shares of stock that are outstanding.
Michael S. Perry, also a director of the company, sold 150,000 shares of the company’s stock on November 21 and November 21. Michael S. Perry is also a director of the company. The total amount received for the sale of the shares was $1,077,000.00, which works out to a price of $7.18 per share on average. As a direct result of the transaction, the director is now the owner of 229,543 shares in the company. The total value of these shares is approximately $1,648,118.74. When you click on this link, you will be taken to a document given to the SEC. This document contains information about the transaction and the presentation given to the SEC. 2.05 company insiders own a percent of the total shares currently outstanding.
On Thursday, the NASDAQ RCEL was $8.71 when trading began. AVITA Medical, Inc. reached an all-time low of $4.41 during the last 52 weeks, while the stock reached an all-time high of $11.00 during the same period. The company has experienced a $6.21 moving average over the previous 200 days and a $6.97 moving average over the most recent fifty days. The company’s current market capitalization value is $218.02 million, its price-to-earnings ratio is -7.32, and its beta value is 1.26.
AVITA Medical (NASDAQ: RCEL) has provided a report to the public revealing its results. This report was made public on November 10. The actual earnings per share generated by the company for the quarter came in at $0.22, which is $0.10 higher than the consensus estimate of $0.32 per share. The return on equity for AVITA Medical was negative by 32.11%, and the net margin for the company was negative by 93.38%. The company’s most recent quarter’s sales came in at $9.09 million, which is significantly higher than the general projection of $7.23 million that market analysts made. According to the forecasts provided by industry professionals, AVITA Medical, Inc.’s current financial year is anticipated to result in losses of $1.22 for each share of common stock.
AVITA Medical, Inc., through its own companies, develops and markets a technological platform that, among other things, makes it possible to perform autologous skin restoration at the point of care to address various unmet needs. This platform aims to fill several gaps in the current medical care system. Their RECELL technology makes it possible for medical professionals to manufacture a suspension of spray-on skin cells to treat severe thermal burns by using a small sample of the patient’s skin as the starting material. This allows for the treatment of burns that would otherwise be impossible.
Conduct research into the business dealings of any other hedge funds that have holdings in RCEL. By going to HoldingsChannel.com, you can research the most recent 13F filings and insider transactions for AVITA Medical, Inc. (NASDAQ: RCEL).